WHO ICTRP trial
Effects of recombinant human GM-CSF on secondary infection and prognosis in the…
ChiCTR2100042925 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100042925 |
|---|---|
| Public title | Effects of recombinant human GM-CSF on secondary infection and prognosis in the immunoparalysis of sepsis |
| Scientific title | Effect of recombinant human GM-CSF on neutrophil extracellular traps and autophagy of polymorphonuclear and the prognosis of sepsis |
| Primary sponsor | Fujian Medical University Union Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | sepsis |
| Interventions | control group:non;thearpy group:rhGM-CSF |
| Registration date | Jan 31, 2021 |
| Target size | control group:50;thearpy group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: